Quest for a broad-range vaccine against Neisseria meningitidis serogroup B: Implications of genetic variations of the surface-exposed proteins

Journal of Medical Microbiology

Volumn 58, Issue 9, 2009, Pages 1127-1132

  De Filippis, Ivano ^a  

^a National Institute for Quality Control in Health   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; LIPOPROTEIN; MENINGOCOCCUS VACCINE; NEISSERIAL SURFACE PROTEIN A; OUTER MEMBRANE PROTEIN; PROTEIN FETA; PROTEIN FHBP; PROTEIN GNA33; PROTEIN NADA; PROTEIN PORB; UNCLASSIFIED DRUG;

BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLINICAL FEATURE; GENETIC VARIABILITY; HAEMOPHILUS INFECTION; HUMAN; IMMUNIZATION; INFLUENZA; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; VACCINATION;

BACTERIAL PROTEINS; GENETIC VARIATION; HUMANS; MEMBRANE PROTEINS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B;

EID: 69049111804     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.011189-0     Document Type: Review

References (51)

1. Beernink, P. T., Leipus, A. & Granoff, D. M. (2006). Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol 13, 758-763.
2. Beernink, P. T., Welsch, J. A., Harrison, L. H., Leipus, A., Kaplan, S. L. & Granoff, D. M. (2007). Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 195, 1472-1479.
3. Bernardini, G., Braconi, D., Martelli, P. & Santucci, A. (2007). Postgenomics of Neisseria meningitidis for vaccines development. Expert Rev Proteomics 4, 667-677.
4. Bisgard, K. M., Kao, A., Leake, J., Strebel, P. M., Perkins, B. A. & Wharton, M. (1998). Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 4, 229-237.
5. Brandtzaeg, P. & Van Deuren, M. (2002). Current concepts in the role of the host response in Neisseria meningitidis septic shock. Curr Opin Infect Dis 15, 247-252.
6. Comanducci, M., Bambini, S., Caugant, D. A., Mora, M., Brunelli, B., Capecchi, B., Ciucchi, L., Rappuoli, R. & Pizza, M. (2004). NadA diversity and carriage in Neisseria meningitidis. Infect Immun 72, 4217-4223.
7. de Filippis, I., do Nascimento, C. R., Clementino, M. B. M., Sereno, A. B., Rebelo, C., Souza, N. N. & Riley, L. W. (2005). Rapid detection of Neisseria meningitidis in cerebrospinal fluid by one-step polymerase chain reaction of the nspA gene. Diagn Microbiol Infect Dis 51, 85-90.
8. Dyet, K. H. & Martin, D. R. (2005). Sequence variation in the porB gene from B : P1.4 meningococci causing New Zealand's epidemic. J Clin Microbiol 43, 838-842.
9. Feil, E. J., Maiden, M. C., Achtman, M. & Spratt, B. G. (1999). The relative contributions of recombination and mutation to the divergence of clones of Neisseria meningitidis. Mol Biol Evol 16, 1496-1502.
10. Frasch, C. E. (2005). Recent developments in Neisseria meningitidis group A conjugate vaccines. Expert Opin Biol Ther 5, 273-280.
11. Gardner, P. (2006). Clinical practice. Prevention of meningococcal disease. N Engl J Med 355, 1466-1473.
12. Giuliani, M. M., Santini, L., Brunelli, B., Biolchi, A., Aricò, B., Di Marcello, F., Cartocci, E., Comanducci, M., Masignani, V. & other authors (2005). The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun 73, 1151-1160.
13. Giuliani, M. M., Adu-Bobie, J., Comanducci, M., Aricò, B., Savino, S., Santini, L., Brunelli, B., Bambini, S., Biolchi, A. & other authors (2006). A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103, 10834-10839.
14. Granoff, D. M., Bartoloni, A., Ricci, S., Gallo, E., Rosa, D., Ravenscroft, N., Guarnieri, V., Seid, R. C., Shan, A. & other authors (1998). Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 160, 5028-5036.
15. Halperin, S. A., Langley, J. M., Smith, B., Wunderli, P., Kaufman, L., Kimura, A. & Martin, D. (2007). Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 25, 450-457.
16. Hammitt, L. L., Block, S., Hennessy, T. W., Debyle, C., Peters, H., Parkinson, A., Singleton, R. & Butler, J. C. (2005). Outbreak of invasive Haemophilus influenzae serotype a disease. Pediatr Infect Dis J 24, 453-456.
17. Hodgson, A., Forgor, A. A., Chandramohan, D., Reed, Z., Binka, F., Bevilacqua, C., Boutriau, D. & Greenwood, B. (2008). A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana. PLoS One 3, e2159.
18. Hou, V. C., Moe, G. R., Raad, Z., Wuorimaa, T. & Granoff, D. M. (2003). Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies. Infect Immun 71, 6844-6849.
19. Jacobsson, S., Thulin, S., Mölling, P., Unemo, M., Comanducci, M., Rappuoli, R. & Olcén, P. (2006). Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 24, 2161-2168.
20. Jódar, L., LaForce, F. M., Ceccarini, C., Aguado, T. & Granoff, D. M. (2003). Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361, 1902-1904.
21. Koeberling, O., Welsch, J. A. & Granoff, D. (2007). Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived neisserial antigen 1870. Vaccine 25, 1912-1920.
22. Koeberling, O., Seubert, A. & Granoff, D. M. (2008). Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 198, 262-270.
23. Maiden, M. C., Malorny, B. & Achtman, M. (1996). A global gene pool in the neisseriae. Mol Microbiol 21, 1297-1298.
24. Martin, S. L., Borrow, R., Van Der Ley, P., Dawson, M., Fox, A. J. & Cartwright, K. A. (2000). Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 18, 2476-2481.
25. Mitka, M. (2005). New vaccine should ease meningitis fears. JAMA 293, 1433-1434.
26. Moe, G. R. & Granoff, D. M. (2001). Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide. Int Rev Immunol 20, 201-220.
27. Moe, G. R., Zuno-Mitchell, P., Hammond, S. N. & Granoff, D. M. (2002). Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 70, 6021-6031.
28. Morelli, G., Malorny, B., Müller, K., Seiler, A., Wang, J. F., del Valle, J. & Achtman, M. (1997). Clonal descent and microevolution of Neisseria meningitidis during 30 years of epidemic spread. Mol Microbiol 25, 1047-1064.
29. Morley, S. L. & Pollard, A. J. (2001). Vaccine prevention of meningococcal disease, coming soon? Vaccine 20, 666-687.
30. Norheim, G., Aase, A., Caugant, D. A., Høiby, E. A., Fritzsønn, E., Tangen, T., Kristiansen, P., Heggelund, U. & Rosenqvist, E. (2005). Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 23, 3762-3774.
31. O'Dwyer, C. A., Reddin, K., Martin, D., Taylor, S. C., Gorringe, A. R., Hudson, M. J., Brodeur, B. R., Langford, P. R. & Kroll, J. S. (2004). Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. Infect Immun 72, 6511-6518.
32. Oliver, K. J., Reddin, K. M., Bracegirdle, P., Hudson, M. J., Borrow, R., Feavers, I. M., Robinson, A., Cartwright, K. & Gorringe, A. R. (2002). Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 70, 3621-3626.
33. Oster, P., Lennon, D., O'Hallahan, J., Mulholland, K., Reid, S. & Martin, D. (2005). MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23, 2191-2196.
34. Perrett, K. P. & Pollard, A. J. (2005). Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther 5, 1611-1625.
35. Rappuoli, R. (2000). Reverse vaccinology. Curr Opin Microbiol 3, 445-450.
36. Rosenstein, N. E., Perkins, B. A., Stephens, D. S., Popovic, T. & Hughes, J. M. (2001). Medical progress: meningococcal disease. N Engl J Med 344, 1378-1388.
37. Rouppe van der Voort, E. , Schuller, M., Holst, J., de Vries, P., Van der Ley, P., Van den Dobbelsteen, G. & Poolman, J. (2000). Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys. Vaccine 18, 1334-1343.
38. Sexton, K., Lennon, D., Oster, P., Crengle, S., Martin, D., Mulholland, K., Percival, T., Reid, S., Stewart, J. & O'Hallahan, J. (2004a). The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. N ZMed J 117, U1015.
39. Sexton, K., Lennon, D., Oster, P., Aaberge, I., Martin, D., Reid, S., Wong, S. & O'Hallahan, J. (2004b). Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand. N Z Med J 117.1 p preceding U1027.
40. Stephens, D. S., Greenwood, B. & Brandtzaeg, P. (2007). Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369, 2196-2210.
41. Suker, J., Feavers, I. M., Corbel, M. J., Jones, C. & Bolgiano, B. (2004). Control and lot release of meningococcal group C conjugate vaccines. Expert Rev Vaccines 3, 533-540.
42. Thomas, M. (2004). Prevention of group B meningococcal disease by vaccination: a difficult task. N Z Med J 117, U1016.
43. Thompson, E. A., Feavers, I. M. & Maiden, M. C. (2003). Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 149, 1849-1858.
44. Tiwana, H., Clow, K. J., Hall, C., Feavers, I. M. & Charalambous, B. M. (2005). The immunogenicity of a conformationally restricted peptide mimetic of meningococcal lipooligosaccharide. Scand J Immunol 62, 385-392.
45. Tsang, R. S. W., Sill, M. L., Skinner, S. J., Law, D. K. S., Zhou, J. & Wylie, J. (2007). Characterization of invasive Haemophilus influenzae disease in Manitoba, Canada, 2000-2006: invasive disease due to nontype B strains. Clin Infect Dis 44, 1611-1614.
46. Unkmeir, A., Kämmerer, U., Stade, A., Hübner, C., Haller, S., Kolb-Mäurer, A., Frosch, M. & Dietrich, G. (2002). Lipooligosaccharide and polysaccharide capsule: virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells. Infect Immun 70, 2454-2462.
47. Urwin, R., Russell, J. E., Thompson, E. A., Holmes, E. C., Feavers, I. M. & Maiden, M. C. (2004). Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 72, 5955-5962.
48. Vermont, C. L. & Van den Dobbelsteen, G. P. (2003). Meningococcal serogroup B infections: a search for a broadly protective vaccine. Expert Rev Vaccines 2, 673-681.
49. Wedege, E., Bolstad, K., Aase, A., Herstad, T. K., McCallum, L., Rosenqvist, E., Oster, P. & Martin, D. (2007). Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol 14, 830-838.
50. WHO (1998). Control of Epidemic Meningococcal Disease, WHO practical guidelines, 2nd edn, WHO/EMC/BAC/98.3. http://www.who.int/emc. Geneva: World Health Organization.
51. Wyle, F. A., Artenstein, M. S., Brandt, B. L., Tramont, E. C., Kasper, D. L., Altieri, P. L., Berman, S. L. & Lowenthal, J. P. (1972). Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 126, 514-521.